Lonquex

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0088/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS A.7 - Administrative change - Deletion of	05/01/2024	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	manufacturing sites				
IAIN/0087	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	21/11/2023	n/a		
IA/0086	A.7 - Administrative change - Deletion of manufacturing sites	08/11/2023		Annex II and PL	
II/0080	Update of section 4.4 of the SmPC in order to add a class-effect warning risk of Acute Myeloid Leukaemia and Myelodysplastic Syndrome in breast and lung cancer patients in conjunction with chemotherapy and/or radiotherapy based on the cumulative review of literature and MAH safety database. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	26/10/2023		SmPC and PL	Based on cumulative review of literature an MAH's safety database, the increased risk of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) in breast and lung cancer patients receiving lipegfilgrastim treatment in conjunction with chemotherapy and/or radiotherapy was assessed. In an observational post-marketing study, MDS and AML were associated with the use of pegfilgrastim, another granulocyte colony-stimulating factor (G-CSF), in combination with chemotherapy and/or radiotherapy in breast and lung cancer patients. A similar association is not known between lipegfilgrastim and MDS/AML. Nevertheless, patients with breast cancer and patients with lung cancer should be monitored for signs and symptoms of MDS/AML. For more information, please refer to the Summary of Product Characteristics.
IAIN/0085	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	26/09/2023	n/a		

IB/0084	B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	12/09/2023	n/a		
IB/0082/G	This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product	06/07/2023		SmPC and PL	
IA/0083	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	05/07/2023	n/a		
IB/0079	B.II.d.2.z - Change in test procedure for the finished product - Other variation	04/07/2023	n/a		
IAIN/0081	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	12/06/2023	n/a		
IB/0078/G	This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	12/05/2023	n/a		

	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation				
R/0077	Renewal of the marketing authorisation.	23/02/2023	19/04/2023	SmPC	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lonquex in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. The Product Information was updated combining the two separate SmPCs for the PFS and vial presentations and is also brought in line with the latest QRD template.
IB/0076	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	16/12/2022	n/a		
IB/0074/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	31/10/2022	n/a		
IAIN/0075	B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	17/10/2022	19/04/2023	SmPC, Labelling and PL	

IB/0073	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	05/10/2022	n/a		
IB/0072/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB	23/08/2022	n/a		
IB/0071	B.I.b.z - Change in control of the AS - Other variation	26/07/2022	n/a		
II/0058/G	This was an application for a group of variations. Extension of indication to include treatment of the paediatric population for Lonquex and introduction of an age appropriate presentation in vials; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC were updated. The Package Leaflet was updated in accordance. Version 14.1 of the RMP has also been agreed. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the	23/06/2022	22/07/2022	SmPC, Labelling and PL	The variation application concerned the extension of indication to paediatric patients (2 years of age and older) and introduction of an age-appropriate presentation in vials. Please refer to Scientific Discussion 'Lonquex-H-C-2556-II-0058/G'.

	Package Leaflet. Furthermore, the PI was brought in line with the latest QRD template version 10.2. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
IB/0070	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	28/03/2022	n/a		
PSUSA/10111 /202107	Periodic Safety Update EU Single assessment - lipegfilgrastim	10/03/2022	n/a		PRAC Recommendation - maintenance
IB/0069	B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	17/12/2021	14/01/2022	SmPC, Labelling and PL	
II/0066	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	28/10/2021	n/a		
IB/0067	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other	27/10/2021	n/a		

	variation				
IA/0065	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	12/07/2021	n/a		
II/0064/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method	08/07/2021	14/01/2022	Annex II and PL	
IB/0063	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	30/04/2021	n/a		
II/0062	Submission of the final report from study XM22-ONC-5002 listed as a category 3 study in the RMP. This is a drug utilisation study on the prescribing patterns of lipegfilgrastim in the EU. The RMP version 13.0 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	11/03/2021	n/a		

II/0060	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	14/01/2021	14/01/2022	Annex II	
IB/0059/G	This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	18/11/2020	n/a		
IB/0061	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	10/11/2020	n/a		
IB/0057/G	This was an application for a group of variations.	28/07/2020	n/a		

	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation				
IB/0056	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	24/06/2020	n/a		
IA/0055	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	29/05/2020	n/a		
IB/0054/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	12/05/2020	n/a		
II/0053/G	This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol	12/09/2019	n/a		

	product and any of the test methods at the site is a biol/immunol method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
II/0048	Update of section 5.1 of the SmPC based on results from study XM22-ONC-40041 listed as an imposed PASS in the Annex II; this is a multinational, multicentre, randomised, double-blind, placebo- and active-controlled study to further investigate the risks of disease progression and mortality associated with lipegfilgrastim. The Annex II and Package Leaflet are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	25/07/2019	13/07/2020	SmPC, Annex II and PL	A post-authorisation safety study XM22-ONC-40041 was conducted to collect data of disease progression and mortality in patients with advanced squamous or non-squamous cell lung cancer receiving lipegfilgrastim in addition to the platinum-based chemotherapy. Increased risk of disease progression or death was not observed with lipegfilgrastim.
IB/0052	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	14/05/2019	n/a		
PSUSA/10111 /201807	Periodic Safety Update EU Single assessment - lipegfilgrastim	28/02/2019	26/04/2019	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10111/201807.
IA/0051/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test	18/04/2019	n/a		

	procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IB/0050	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	18/02/2019	26/04/2019	SmPC and PL	
IB/0049	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	15/02/2019	n/a		
T/0046	Transfer of Marketing Authorisation	13/12/2018	21/01/2019	SmPC, Labelling and PL	
IA/0047/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	12/12/2018	n/a		
IB/0044	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	24/10/2018	21/01/2019	SmPC and PL	
II/0041/G	This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The	13/09/2018	n/a		

	change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other				

	variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS				
IAIN/0043	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	26/07/2018	21/01/2019	Annex II and PL	
IB/0042	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	05/07/2018	n/a		

IB/0040	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	15/05/2018	n/a		
R/0039	Renewal of the marketing authorisation.	22/02/2018	08/05/2018	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lonquex in the approved indication remains favourable, but recommended that one additional five-year renewal be required based on the following pharmacovigilance grounds: The currently ongoing imposed post-authorisation safety study XM22-ONC-40041 to further investigate the risks of disease progression and mortality associated with Lonquex in patients with malignancy treated with cytotoxic chemotherapy is key to the benefit-risk profile of the product. The final report for this study is due in December 2018. Therefore, based upon the safety profile of Lonquex, which requires the submission of yearly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years' time. In addition, sections 4.4 and 4.8 of the SmPC were updated to mention that events of glomerulonephritis have been reported in patients receiving filgrastim or pegfilgrastim and that these events generally, resolved after dose reduction or withdrawal of filgrastim and pegfilgrastim. Urinalysis monitoring is recommended. The package leaflet has been amended accordingly.

PSUSA/10111 /201707	Periodic Safety Update EU Single assessment - lipegfilgrastim	08/02/2018	n/a		PRAC Recommendation - maintenance
IB/0035	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	04/10/2017	n/a		
IA/0036	A.7 - Administrative change - Deletion of manufacturing sites	13/09/2017	08/05/2018	Annex II and PL	
IAIN/0037	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	07/09/2017	08/05/2018	Annex II and PL	
IA/0034/G	This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits	10/08/2017	n/a		
IB/0033	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	16/05/2017	n/a		

II/0030/G	This was an application for a group of variations. B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs B.I.c.1.z - Change in immediate packaging of the AS - Other variation	16/03/2017	n/a		
IB/0032	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	13/03/2017	n/a		
PSUSA/10111 /201607	Periodic Safety Update EU Single assessment - lipegfilgrastim	09/02/2017	n/a		PRAC Recommendation - maintenance
II/0027	B.I.d.1.a.3 - Stability of AS - Change in the re-test period/storage period - Extension of storage period of a biological/immunological AS not in accordance with an approved stability protocol	15/09/2016	n/a		
II/0025/G	This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release	15/09/2016	n/a		

	arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)				
PSUSA/10111 /201601	Periodic Safety Update EU Single assessment - lipegfilgrastim	02/09/2016	n/a		PRAC Recommendation - maintenance
IAIN/0028/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or	08/07/2016	20/04/2017	Annex II and PL	

	manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release				
II/0023	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	26/05/2016	20/04/2017	SmPC, Labelling and PL	Generally asymptomatic cases of splenomegaly have been reported after administration of lipegfilgrastim and infrequent cases of splenic rupture, including fatal cases, have been reported after administration of G CSF or derivatives. Spleen size should therefore be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic rupture should be considered in patients reporting left upper abdominal pain or shoulder tip pain.
IB/0026/G	This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	24/05/2016	n/a		
IB/0022	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting	25/02/2016	n/a		

	material/intermediate				
PSUSA/10111 /201507	Periodic Safety Update EU Single assessment - lipegfilgrastim	11/02/2016	n/a		PRAC Recommendation - maintenance
IB/0021	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	04/12/2015	n/a		
IB/0019	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	17/09/2015	n/a		
IB/0018	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	17/09/2015	n/a		
PSUSA/10111 /201501	Periodic Safety Update EU Single assessment - lipegfilgrastim	10/09/2015	n/a		PRAC Recommendation - maintenance
IB/0017/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement	22/07/2015	n/a		

	or addition) for the AS or a starting material/intermediate				
IB/0014	C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority	16/06/2015	02/06/2016	SmPC and PL	
IA/0015/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test	22/05/2015	n/a		
IB/0016	B.II.f.1.e - Stability of FP - Change to an approved stability protocol	21/05/2015	n/a		
IB/0011	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	13/05/2015	n/a		
IB/0012	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	20/03/2015	28/05/2015	Annex II	

PSUSA/10111 /201407	Periodic Safety Update EU Single assessment - lipegfilgrastim	12/02/2015	n/a		PRAC Recommendation - maintenance
IAIN/0010/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	10/02/2015	28/05/2015	SmPC, Labelling and PL	
IB/0009/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	02/12/2014	n/a		
II/0004	Update of the product information in order to include information regarding capillary leakage syndrome (CLS); a class effect of granulocyte-colony stimulating factors (G-CSFs).	20/11/2014	28/05/2015	SmPC, Annex II and PL	Following the review of potential signals of capillary leak syndrome (CLS) and cytokine release syndrome in association with filgrastim and pegfilgrastim, the PRAC recommended that the product information for all G-CSFs be updated to include the undesirable effect of capillary

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				leak syndrome. Consequently, the MAH has submitted a variation to update SmPC and PIL for lipegfilgrastim to include warnings and information on CLS. Sections 4.4 and 4.8 of the SmPC have been updated to include that CLS, which can be life threatening if treatment is delayed, has been reported mostly in cancer patients undergoing chemotherapy after administration of G-CSF or derivatives. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.
IB/0008	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	14/11/2014	n/a		
IB/0006/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	30/09/2014	n/a		
PSUV/0002	Periodic Safety Update	11/09/2014	n/a		PRAC Recommendation - maintenance

IAIN/0005/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	12/08/2014	n/a		
IAIN/0003/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.7 - Administrative change - Deletion of manufacturing sites	20/06/2014	28/05/2015	Annex II and PL	

T/0001	Transfer of Marketing Authorisation from Teva Pharma B. V. to UAB 'Sicor Biotech'. Transfer of Marketing Authorisation	27/03/2014	10/04/2014	SmPC, Labelling and PL	